References
- Lombardi G, Zustovich F, Farina P, Della Puppa A, Manara R, Cecchin D, . Neoplastic meningitis from solid tumors: New diagnostic and therapeutic approaches. Oncologist 2011;16:1175–88.
- Stemmler HJ, Schmitt M, Harbeck N, Willems A, Bernhard H, Lassig D, . Application of intrathecal trastuzumab (HerceptinTM) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 2006;15:1373–7.
- National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers. v.1.2012. Accessed 2012 Mar 7. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.
- Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, . A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999;5: 3394–402.
- Boogerd W, van den Bent MJ, Koehler PJ, Heimans JJ, van der Sande JJ, Aaronson NK, . The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: A randomized study. Eur J Cancer 2004;40:2726–33.
- Rudnicka H, Niwinska A, Murawska M. Breast cancer leptomeningeal metastasis – the role of multimodality treatment. J Neurooncol 2007;84:57–62.
- Laufman LR, Forsthoefel KF. Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer 2001;2:235 (letter).
- Platini C, Long J, Walter S. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 2006;7:778–80.
- Stemmler HJ, Mengele K, Schmitt M, Harbeck N, Laessig D, Hermann KA, . Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: A case report. Anticancer Drugs 2008;19:832–6.
- Shojima K, Suzuki E, Saito K, Sekine D, Kitagawa T, Aruga S, . Application of intrathecal trastuzumab for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. J Clin Oncol 2008;26(Suppl);1138 (abstract).
- Mir O, Ropert S, Alexandre J, Lemare F, Goldwasser F. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol 2008;19:1978–80 (letter).
- Colozza M, Minenza E, Gori S, Fenocchio D, Paolucci C, Aristei C, . Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab. Cancer Chemother Pharmacol 2009;63:1157–9.
- Ferrario C, Davidson A, Bouganim N, Aloyz R, Panasci LC. Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. Ann Oncol 2009;20:792–5 (letter).
- Allison DL, Glantz M, Werner TL, Kirkegaard SL, Murdock K, Jensen R. Intra-CSF trastuzumab in patients with neoplastic meningitis from breast cancer or primary brain tumors. J Clin Oncol 2009;27(Suppl):2066 (abstract).